> All the big AIM fraud exposés
> 300 articles and podcasts a month
> Hot share tips
> Original investigations by our experienced team
> No ads, no click-bait, no auto-play videos
AIM listed fraud Cloudtag (CTAG) has unveiled the rebrand of its product which may or may not exist and which despite being first launched almost a year ago has generated sales of exactly 0. That this has excited the moronic shareholders of this company as the followed the countdown clock on the company's website says everything about the pea-brained fools,
Hello Share Tasters. I hold more Trinity Mirror (TNI) shares than I am happy with. It’s the usual story of having invested many, many years ago and then failing to wave bye bye when the story changes for the worst.
Some folks are winding down for Christmas already. Idle wotsits! Steve Moore and I are, however very much hard at work and we will have not one but TWO fantastic share tips coming out TODAY, Friday 16th December, at 2 PM. Christmas shopping can wait. These share tips are too hot. They can't!
I start with a few explanations of how businesses work and how markets work for shareholders in Cloudtag (CTAG) and Optibiotix (OPTI), Then I mention two risers, Falanx (FLX) and Andalas (ADL) before moving on to Marechale (MAC), MySquar (MYSQ) and finally, in great detail, the 17 years of jam tomorrow bollocks that is Torotrak (TRK). Remember, as per podcast, - five share tips for a fiver - starts Monday at 7 AM, don't miss out sign up HERE
Earlier this week, Xtract Resources (XTR) announced an upcoming EGM to authorise the issuance of a further 9 billion shares, a mere 50% of the current share capital! Sounds like a lot but one needs to have a look again at the last heavily dilutive funding round in November to ascertain whether this is actually going to help.
Yesterday’s staggering RNS from CloudTag (CTAG) has already been covered brilliantly in the CloudTag Bearcast special with Tom Winnifrith at his acerbic best – an absolute must-listen - but I have a couple of other observations and am unable to leave the L1 conversion notice date lie alone just yet!
As joint house broker to the exponent of Securities fraud that is Advanced Oncotherapy (AVO), Beaufort has to sound bullish and has thus reiterated its speculative buy stance today. But read the note carefully. Beaufort is frit. I have highlighted key phrases that have not appeared before for you. Key phrases which show goalposts being moved and a broker that is sick of being made to look foolish.
Nomad Cairn has not resigned as adviser to Cloudtag (CTAG) even though it has lied to investors on a serial basis and committed Securities fraud. Cairn's reputation is thus in tatters. It thus begs the question of how any of its other clients are frauds, how many are simply not investment grade material and how many of the few good clients will want to be associated with the disgraced Nomad for much longer as it will not help their share prices to be linked to this rotten, stinking adviser. The clients are listed below by AIM or ISDX category.
Well I guess it is not dead yet, but ShareProphets AIM-China Filthy Forty poster-boy MoneySwap (SWAP) sure is pushing the line. Having bundled through shareholder authorities to get enough headroom available for a rescue bail-out at its last AGM even without a firm proposal on the table last June, apparently due to the urgency of the situation, here we are six months on and still there is no deal – and the company is running on the fumes of a series of emergency loans. What’s the point?!
On 29 November Optibiotix (OPTI) stated: "OptiBiotix reports that it has reached late stage commercial discussions with six commercial partners across its technology and product platforms.". The knockers said "jam tomorrow won't happen". This week the first of the six deals was announced and it is massive. More will follow as Adam Reynolds made clear yesterday exclusively HERE. The news is:
Now for the drill down in detail on the horseshite served up by liars and fraudsters Cloudtag (CTAG) and morally bankrupt Nomad Cairn in yesterday's disgraceful RNS - the overall take is HERE. Let us now look at the new distributor in the UK and Europe Nemesis. It will work alongside Second Chance which used to have an exclusive deal and was guaranteeing 2016 sales of $5.2 million, It has delivered nil. So will Nemesis do any better?
An easy odd one out contest. Which of the four below is the odd one out and why? Answers in the comments section below - deadline midnight Saturday 17 December.
Wow! I’d love to have been a fly on the wall over at Cairn Financial as the wording of last night’s no-one-is-watching-o’clock RNS from AIM-listed CloudTag (CTAG) was being, ahem, “discussed.” I wonder how long that lot took to put together….since last Friday? It was a real shocker.
Cloudtag (CTAG) has released an after hours RNS. It beggars belief that Nomad Cairn has signed off on this shite, More lies to compound earlier lies but also an admission of more breaches of AIM Rules and that 2016 sales will be zero, contrary to earlier lies. It is all utter horseshite and in this special podcast I take apart this statement bit by bit. It is a bad day for AIM. Cairn you should be ashamed and is beneath contempt. Cloudtag has lied and committed fraud and its shares are a sell with a 0p target.
Hello Share Pickers. I'm in the middle of one of those interminable train journeys where you pass loads of familiar town names everybody knows, but where nobody ever stops. In this case Wilmslow, Hereford, Leominster, Ludlow, Crewe, Craven Arms etc. Well, have you ever been there?
Earlier Adam and I chatted about Concepta (CPT). In this podcast we cover Optibiotix (OPTI) and Premaitha (NIPT).
In this podcast I revisit the vexed subject of Xtract Resources (XTR) which begs the question of when exactly I should sack Gary Newman and Steve Moore. Having seen a Christmas Carol last night I am inspired by my hero Scrooge, that is to say before he got all soppy, Guardian reading and pathetic in his old age. I also comment on Management Consulting (MMC) before returning at length to Cloudtag (CTAG). This time I play the ghost of Christmases yet to come with a warning for hapless Nomad Cairn. I also comment on Sula (SULA) with whom I met up yesterday.
Yesterday I was explaining how silly it was to say I was bashing Cloudtag (CTAG) because its CEO is Jewish. I am an ardent zionist and very keen on the Jews. The Welsh however, that is another matter altogether. Where do I start when it comes to the race of short, untrustworthy, bone idle, sheep molesting, welfare addicted whingers who blame all their woes on the English? Oh yes, I met a nice Welshman yesterday. Don't get me wrong some of my best friends are Welsh. Well my daughter anyway.
We tipped Amryt Pharma (AMYT) pre-consolidation at an effective 18.4p earlier this year and until last week it all went quiet. Now it has roared into life and the shares are 18.5p-20.5p. So what happened? And what next?
I sat down with Adam Reynolds, the shellmeister today and recorded a string of podcasts. This one is on Concepta (CPT) a stock we own. The shares are 16p-17p. IMHO they should be closer to 30p. The next six months will see masses of news and real, material, sales and that will, I'm sure, drive a real re-rating of the shares. Listen to what Adam says...
Amit Ben Haim does not like to be at the helm when one of his enterprises goes belly up. He always quits and leaves a gent called Massimo Ventimiglia to pick up the pieces. And hence we come to Cloudtag (CTAG) subsidiary CT Technology Services.
Thank God for small mercies. Now we can start a rota on who has to listen to Brokerman Dan blathering on about blockchain and what a frigging genius Clem Chambers is. For now there is a third rogue blogger joining us as we walk the 32 miles from Horse Hill to Woodlarks on July 28. He is a man who knows Horse Hill well…
Maybe Julie "Lingerie on expenses" Meyer MBE thought Winnileaks was on holiday. Winnileaks never rests. Our latest document shows Julie playing fast and loose with the truth as she ballted to avoid facing justice against the Start Up Loans Company.
It is not as if Optibiotix (OPTI) management do not put their money where their mouth is. Just a few days ago chairman Neil Davidson splashed out £150,000 buying shares at 71p. Now we have news of an option package for three senior staffers including Davidson. No options….one way bet… nooooooooooooo you scream. No. Read the RNS.
Shares in Westminster Group (WSG), run by loathsome ex Tory MP slug, Tony “fatso” Baldry of 3DM infamy have slipped again to just 9.2p to sell. Those who ponied up £750,000 in the last bailout placing at 22p, less than six months ago, must by now realise that backing a Baldry run company is financial hara kiri. But things are going to get worse. You see the money's almost gone....
Hello Share Chewers. Small pioneering medical companies are a favourite of mine. As finding a cure for a condition which is so often overlooked by the giant pharmas has to be a good thing. Both from the point of view of patients and that of shareholders.
The extract from the Land Registry below is in the public domain and looks like a huge misunderstanding to me. Worthington (WRN) may be in administration but it seems the FCA have a few questions for its former boss Doug Ware. I am sure there is a perfectly innocent explanation for all of this.
Oh dear, I sense that in my adopted home of Greece there are a few folks heading for the slammer in connection with the Folli Follie Fraud which we helped Gabriel Grego to expose on this website. It seems like just the other day that burly security guards were chasing me away from its HQ North of Athens, as you can see HERE.
Maybe Julie "Lingerie on expenses" Meyer MBE has other problems to consider? Take it from me that she does. There is more to follow, the wheels are a turning. But perhaps she or her uber expensive bully boy lawyer Julian Pike might answer a simple question for me. It relates to ASX listed Norwood.
Amino Technologies (AMO) has announced results for its half year ended 31st May 2018, emphasising “strong revenue visibility and pipeline coverage - full year expectations confirmed” - the numbers though showing adjusted earnings approaching 60% lower than in the corresponding half in the prior year on revenue 17% lower at $41.2 million. Hmmm…
Not much has got me fired up so far this week looking at the various regulatory disclosures but I did notice an article in the newspaper that purports to be America's leading financial journal yesterday with the worrisome headline of 'Barclays Mulls U.S. Push as Activist Looms...Executives debate whether greater exposure to the U.S. retail market could both generate revenues and fund its U.S. operations more efficiently'…
I’ve touched on Immunocore a few times in passing as it one of the largest holdings in Woodford Patient Capital Trust (WPCT) as well as being the largest investment made by Dublin-listed Malin Corporation, of which Woodford is the largest shareholder, obvs! Well, it looks like it’s not a particularly happy ship and I wonder whether a (further) devaluation is required?
In this week's video update from Palisade Capital and the only technical analyst we give any time to at all, Jordan Roy Burne discusses where the market is and why it failed to break-out. Traders were anticipating a breakout, and many are likely disappointed. The dollar is consolidating and now above the long-term moving average. Concerning GDX and GDX.J, things are still pretty dull. Jordan warns that “Silver is also on the verge of breaking down out of a triangle.”
Previously writing on Cloudcall (CALL) it was 2017 results, emphasises significant reduction in cash burn… but is there?, with the shares more than 6% lower, towards 165p. Today a half-year trading update – and the shares currently down around 10%, at circa 140p…
Shares in Image Scan Holdings (IGE) reached approaching 13p last year and were 6p+ following half-year results in April before sliding in the last month, last closing at 5.5p. Now an “Acquisition and Proposed Placing” announcement…
Previously writing on SRT Marine Systems (SRT) in April, I concluded with previous delays and a current market cap of more than £30 million, I await to see evidence it is actually on-track as well as the cash flow and the balance sheet. Today a “SE Asia Contract Change” announcement…
I commented on the lunatic management at Premier Foods (PFD) a couple of weeks ago HERE, who, after turning down a perfectly good bid, are circling the wagons against activist investors who want to help to start to create value by booting out the CEO. I could not agree more with their assertion that the CEO's tenure is 'five year of failure'...
Search ShareProphets |
Stock market news |
Complete Coverage |
Recent Comments |
Site by Everywhen